- Home
- CLB vs SVRA Comparison
CLB vs SVRA Comparison
Compare CLB & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- SVRA
- Stock Information
- Founded
- CLB 1936
- SVRA 2007
- Country
- CLB United States
- SVRA United States
- Employees
- CLB N/A
- SVRA N/A
- Industry
- CLB
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- CLB
- SVRA Health Care
- Exchange
- CLB Nasdaq
- SVRA Nasdaq
- Market Cap
- CLB 482.5M
- SVRA 527.2M
- IPO Year
- CLB 1995
- SVRA N/A
- Fundamental
- Price
- CLB $11.16
- SVRA $3.16
- Analyst Decision
- CLB Hold
- SVRA Buy
- Analyst Count
- CLB 2
- SVRA 7
- Target Price
- CLB $12.50
- SVRA $5.57
- AVG Volume (30 Days)
- CLB 450.4K
- SVRA 1.3M
- Earning Date
- CLB 07-23-2025
- SVRA 08-13-2025
- Dividend Yield
- CLB 0.36%
- SVRA N/A
- EPS Growth
- CLB 23.99
- SVRA N/A
- EPS
- CLB 0.62
- SVRA N/A
- Revenue
- CLB $517,378,000.00
- SVRA N/A
- Revenue This Year
- CLB N/A
- SVRA N/A
- Revenue Next Year
- CLB $2.24
- SVRA N/A
- P/E Ratio
- CLB $17.96
- SVRA N/A
- Revenue Growth
- CLB 0.70
- SVRA N/A
- 52 Week Low
- CLB $9.72
- SVRA $1.89
- 52 Week High
- CLB $21.83
- SVRA $4.70
- Technical
- Relative Strength Index (RSI)
- CLB 52.96
- SVRA 71.42
- Support Level
- CLB $10.15
- SVRA $2.92
- Resistance Level
- CLB $10.72
- SVRA $3.28
- Average True Range (ATR)
- CLB 0.45
- SVRA 0.21
- MACD
- CLB 0.09
- SVRA 0.04
- Stochastic Oscillator
- CLB 97.30
- SVRA 85.88
About CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.